Integrative proteomic and gene expression analysis identify potential biomarkers for adjuvant trastuzumab resistance: analysis from the Fin-her phase III randomized trial

Trastuzumab is a remarkably effective therapy for patients with human epidermal growth factor receptor 2 (HER2)--positive breast cancer (BC). However, not all women with high levels of HER2 benefit from trastuzumab. By integrating mRNA and protein expression data from Reverse-Phase Protein Array Ana...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Oncotarget 2015-10, Vol.6 (30), p.30306-30316
Hauptverfasser:	Sonnenblick, Amir, Brohée, Sylvain, Fumagalli, Debora, Rothé, Françoise, Vincent, Delphine, Ignatiadis, Michael, Desmedt, Christine, Salgado, Roberto, Sirtaine, Nicolas, Loi, Sherene, Neven, Patrick, Loibl, Sibylle, Denkert, Carsten, Joensuu, Heikki, Piccart, Martine, Sotiriou, Christos
Format:	Artikel
Sprache:	eng
Schlagworte:	Annexin A1 - genetics Biomarkers, Tumor - analysis Biomarkers, Tumor - antagonists & inhibitors Biomarkers, Tumor - genetics Breast Neoplasms - chemistry Breast Neoplasms - diagnosis Breast Neoplasms - drug therapy Breast Neoplasms - genetics Breast Neoplasms - pathology Chemotherapy, Adjuvant Clinical Research Paper Databases, Genetic Disease Progression Disease-Free Survival Drug Resistance, Neoplasm - genetics Female Finland Gene Expression Profiling - methods Gene Expression Regulation, Neoplastic Genetic Predisposition to Disease Humans Kaplan-Meier Estimate Multivariate Analysis Patient Selection Phenotype Predictive Value of Tests Proportional Hazards Models Prospective Studies Protein Array Analysis Protein Kinase Inhibitors - therapeutic use Proteomics - methods Receptor, ErbB-2 - analysis Receptor, ErbB-2 - antagonists & inhibitors Reproducibility of Results Risk Factors Time Factors Trastuzumab - therapeutic use Treatment Outcome
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!